ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1426	National Cancer Institute	Html	en	Childhood Ependymoma Treatment (PDQ®)–Health Professional Version	In childhood ependymoma, cancer forms in the tissues of the brain and spinal cord. The cause of ependymoma is unknown. Find out about the molecular and clinical features, diagnosis, prognosis, treatment, and clinical trials for pediatric ependymoma, subependymoma, myxopapillary ependymoma, anaplastic ependymoma, and RELA fusion–positive ependymoma.	childhood recurrent ependymoma 0.446141 Merchant TE 0.374501 Brain Tumor Registry 0.351132 childhood brain tumor 0.35242 spinal cord ependymomas 0.479172 nervous system ependymoma 0.395153 posterior fossa ependymoma 0.628195 brain tumors 0.516421 children 0.409198 malignant brain tumors 0.384396 newly diagnosed ependymoma 0.411931 Sayegh ET 0.377382 Int J Radiat 0.476989 Radiat Oncol Biol 0.6983 World Health Organization 0.41477 intracranial ependymoma recurrence 0.508211 pediatric supratentorial tumors 0.369961 posterior fossa tumors 0.3562 infratentorial ependymoma 0.423041 ependymoma patients 0.42421 intracranial ependymomas 0.39986 Supratentorial ependymoma 0.435338 Clin Cancer Res 0.386576 paediatric ependymoma 0.450128 pediatric intracranial ependymoma 0.570833	radiation therapy 0.449829 Acta Neuropathol 0.35243 et al. 0.743726 childhood ependymoma 0.513088 intracranial ependymoma 0.927373 recurrent ependymoma 0.45402 Neuro Oncol 0.356088 primary brain tumors 0.39985 pediatric intracranial ependymomas 0.371298 adult ependymoma cases 0.44321 Pediatr Blood Cancer 0.534048 childhood ependymomas 0.358916 Metastatic ependymoma 0.401089 posterior fossa ependymomas 0.381573 spinal cord 0.504643 Abstract 0.696 non-anaplastic ependymoma 0.396839 childhood intracranial ependymoma 0.687299 Clin Oncol 0.484182 childhood brain tumors 0.3515 Oncol Biol Phys 0.714533 spinal canal ependymoma 0.421296 Central Brain Tumor 0.351707 Childs Nerv Syst 0.489135	CLICK HERE
1481	National Cancer Institute	Html	en	Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of thymoma and thymic carcinoma.	invasive thymic carcinoma 0.363485 thymic carcinoma. 0.329556 survival rates 0.580103 2-year survival rates 0.392508 chemotherapy 0.354257 thymic epithelial tumors 0.386833 carefully selected patients 0.325286 standard fractionation scheme 0.338104 thymic epithelial lesions 0.330628 overall survival 0.330513 capsular invasion 0.323485 thymoma 0.610197 preoperative radiation therapy 0.322721 World Health Organization 0.442231 thymic epithelial cells 0.331631 thymomas 0.354387 patients 0.764093 spindle cell thymoma 0.322148 stage IV thymoma 0.32289 stage iii thymoma 0.335721 radiation therapy 0.804549 stage IV patients 0.32869 thymic carcinomas 0.503693 aggressive surgical resection 0.324008 complete resection 0.446452	et al. 0.348745 stage II thymoma 0.324351 thymic carcinoma 0.971315 myasthenia gravis 0.600465 5-year survival rate 0.446228 surgical resection 0.369944 thymic epithelial tumor 0.413556 additional radiation therapy 0.3642 adjuvant radiation therapy 0.463546 Ann Thorac Surg 0.423155 totally resected stage 0.398025 total resection 0.362037 5-year survival 0.507881 multimodality treatment 0.32997 Malignant thymoma 0.395719 Thorac Cardiovasc Surg 0.368885 completely resected thymoma 0.339207 Abstract 0.372345 earlier stage disease 0.331389 Masaoka clinical stage 0.43597 Paraneoplastic myasthenia gravis 0.390824 histologic classification 0.344613 thymoma cases 0.332006 5-year survival rates 0.449523	CLICK HERE
1847	National Cancer Institute	Html	es	Tratamiento del cáncer de vejiga (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de vejiga.	Ta T1 bladder 0.362863 BCG vs 0.318538 prognostic factors 0.316381 urinary tract tumors 0.311024 quimioterapia intravesical posoperatoria 0.468241 Sin embargo 0.334145 G1Ta bladder 0.318831 risk groups 0.312464 stage t1 tumors 0.314985 bladder cancer 0.962527 Bladder Cancer Meta-analysis 0.326886 Tumor progression 0.313249 Millán-Rodríguez F 0.322816 pelvis renal 0.364298 Malignant bladder tumors 0.321161 non-muscle-invasive urothelial carcinoma 0.385032 stage ta t1 0.32667 bladder tumors 0.386807 Estados Unidos 0.326159 Natl Cancer Inst 0.319662 Manoharan M 0.311152 patients with 0.393406 Chéchile-Toniolo G 0.322599 Babjuk M 0.331941 vejiga ta 0.335749	Sylvester R 0.333215 Ta urothelial carcinoma 0.313829 Eur Urol 0.378134 vejiga carcinomas 0.326934 urinary tract 0.330369 with stage ta 0.327583 bladder followed 0.317421 BCG intravesical demora 0.315841 Cancer Staging Manual 0.319905 Soloway MS 0.311003 cell carcinoma 0.326726 patients with stage 0.336429 Salvador-Bayarri J 0.322164 Sylvester RJ 0.317663 urinary bladder 0.354046 Clin Oncol 0.331355 Oosterlinck W 0.385864 EAU guidelines 0.334682 urothelial carcinoma 0.440061 bladder toxicity from 0.319949 vejiga estadio 0.322563 Radical cystectomy 0.328383 AJCC Cancer Staging 0.320707 metastatic urothelial carcinoma 0.311479	CLICK HERE
1865	National Cancer Institute	Html	es	Tratamiento de los síndromes mielodisplásicos (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los síndromes mielodisplásicos.	int-1-risk mds with 0.306049 displasia multilinaje 0.307414 results from 0.303983 granulocyte colony-stimulating factor 0.309016 neoplasias mieloides 0.312984 Garcia-Manero G 0.313072 único tratamiento 0.304306 with erythropoietin 0.312779 anomalía citogenética 0.307792 fase ii 0.312681 international prognostic scoring 0.321295 anomalías citogenéticas 0.312714 randomized study 0.305169 risk factors 0.304186 stem cell transplantation 0.306118 displasia unilinaje 0.30428 PDQ Fatiga 0.308455 Hypoplastic myelodysplastic 0.304869 syndromes treated with 0.307198 MDS with 0.310074 patients with 0.448968 with granulocyte colony-stimulating 0.305945 patients with lower 0.307744 marrow transplantation 0.304031 células madre 0.305457	crecimiento mieloide 0.304117 leucemia aguda 0.308968 elderly patients with 0.307457 síndromes mielodisplásicos 0.421016 Anderson Cancer Center 0.305709 hematopoietic stem-cell transplantation 0.306245 syndrome results 0.304563 SMD neutropénicos asintomáticos 0.311641 PDQ Tratamiento 0.30516 MD Anderson Cancer 0.305795 PDQ Neoplasias 0.304911 Clin Oncol 0.347749 US patients with 0.307961 Sekeres MA 0.309258 Kantarjian H 0.309886 Conditioning with targeted 0.305451 Hellström-Lindberg E 0.307604 prognostic scoring system 0.330511 leucemia mieloide aguda 0.3404 treated with 0.308208 with recombinant 0.304816 patients with myelodysplastic 0.404348 from patients with 0.307143 myelodysplastic syndrome 0.965311	CLICK HERE
1879	National Cancer Institute	Html	es	Tratamiento del cáncer de seno (mama) en el embarazo (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama) en el embarazo.	Chua T 0.308433 Rugo HS 0.308741 exposed to chemotherapy 0.30311 Surg Gynecol Obstet 0.330452 outcome after 0.304299 pregnant patient 0.315879 anomalías congénitas 0.308598 Clark RM 0.307911 Theriault R 0.32478 cancer diagnosed during 0.342035 diagnosed during pregnancy 0.34332 Loprinzi CL 0.304379 Sin embargo 0.313532 patient with carcinoma 0.318411 mother during gestation 0.303218 Instituto Nacional 0.305213 Petrek JA 0.304025 Yang WT 0.304051 breast carcinoma during 0.308603 breast carcinoma 0.313568 Gynecol Oncol 0.302701 altas concentraciones 0.304242 cancer diagnosed 0.35036 safety after breast 0.308046 chemotherapy during pregnancy 0.3192	Curr Treat Options 0.317342 administration during pregnancy 0.307821 overall survival after 0.302827 R Coll Radiol 0.316078 Wallack MK 0.309132 Gallenberg MM 0.304139 ultimate challenge 0.308285 Surg Clin North 0.303453 National Cancer Institute 0.306047 during pregnancy 0.532041 Surg Oncol 0.303192 pregnant patient with 0.318156 PDQ Tratamiento 0.303689 after maternal cancer 0.306691 Clin Oncol 0.325015 Radiotherapy during pregnancy 0.307723 breast cancer 0.976679 systematic review 0.303372 Treat Options Oncol 0.318121 Dryden MJ 0.304024 breast cancers from 0.308506 with or without 0.302892 as systemic treatment 0.302539 Gwyn K 0.36898	CLICK HERE
1977	National Cancer Institute	Html	es	Tratamiento del carcinoma de corteza suprarrenal (PDQ®)–Versión para pacientes	Resumen de revisión revisada por expertos acerca del tratamiento del carcinoma de corteza suprarrenal.	siguientes procedimientos 0.496457 tinte circula 0.500083 pequeña cantidad 0.426407 estadio ii 0.722852 vía oral 0.42258 rayos x 0.485722 ondas sonoras 0.428325 National Cancer Institute 0.418399 sustancia llamada gadolinio 0.451231 suprarrenal elabora hormonas 0.951617 siguientes riesgos 0.416128 secciones cáncer 0.564083 Instituto Nacional 0.51582 PDQ Tratamiento 0.443801 siguientes hormonas 0.456613	presente sección 0.419609 corteza suprarrenal causa 0.829807 siguientes funciones 0.454626 Physician Data Query 0.471125 médula suprarrenal.Ampliar 0.44071 estadio iii 0.71977 características masculinas 0.438548 siguientes enfermedades 0.449744 PDQ Feocromocitoma 0.493816 suprarrenal causa efectos 0.739636 siguientes terapias 0.423482 PDQ Cánceres 0.484481 siguientes enlaces 0.420507 suprarrenal funcionante elabora 0.710246 siguientes pruebas 0.503631	CLICK HERE
2076	National Cancer Institute	Html	es	Alcohol y el riesgo de cáncer	Hoja informativa que resume la comprobación de la relación entre el consumo de alcohol y el riesgo de varios cánceres. Incluye información de los factores que afectan el riesgo de cánceres asociados con el alcohol, como son los genes y el uso de tabaco.	Neck Cancer Epidemiology 0.538614 Lancet Oncology 0.534891 Hirose K 0.511352 Matsuo K 0.510531 levadura fermenta azúcares 0.523222 pharyngeal cancers 0.510877 Alcohol drinking cessation 0.626157 British Journal 0.511017 vitamina a 0.51094 Straif K 0.510855 vitamina e 0.511443 IARC Monographs 0.512402 IARC Working Group 0.518509 riesgos resultantes 0.517271 Estados Unidos 0.591854 alcohol drinking 0.759868 Tajima K 0.511125 PubMed Abstract 0.957874 neck cancers 0.610459 Cancer Epidemiology 0.551257 Beral V 0.510723 Liver Disease 0.511887 cancer prevention 0.54975 alcohol consumption with 0.621668 vino tinto 0.531211	results from subgroup 0.518268 International Head 0.510721 Fedirko V 0.510662 contaminantes cancerígenos 0.510849 Carcinogenic Risks 0.530612 ADH hiperactiva 0.535244 Numerosos estudios 0.516257 preclinical studies 0.511192 enzima hiperactiva 0.522144 Bonifazi M 0.510536 epidemiological studies 0.512501 Hodgkin lymphoma 0.511109 enzima adh hiperactiva 0.532963 Tramacere I 0.552596 genetic polymorphisms 0.530043 enzima llamada 0.519065 Bagnardi V 0.51066 Rehm J 0.529488 cabo estudios 0.515059 pooled analysis 0.527827 renal cell carcinoma 0.521274 Cancer Institute 0.525901 células renales 0.53114 New York Academy 0.514614	CLICK HERE
2988	National Cancer Institute	Html	en	Secondhand Smoke	Smoking affects both you and your loved one's health. Learn about the consequences of secondhand smoke and how you can protect your family.	feet 0.409991 dangers 0.420271 Lung cancer 0.428942 good example 0.428021 non-smoker 0.407426 care staff 0.426607 nicotine affect 0.427281 babysitters 0.406286 body 0.411562 smoker 0.414092 children 0.431937 harms 0.407652 sure caretakers 0.428123 secondhand smoke 0.971613 non-smokers 0.43912 heart disease‚ 0.429635 Fact 0.410452 short time 0.429909 somebody 0.406088 health problems 0.428728 smokefree restaurants 0.432863 lung infections 0.428228 smoking indoors 0.445671 main way smoking 0.477206 Breathing problems 0.428866	indoor public places 0.450365 babies 0.424287 smokers 0.419121 air 0.417572 life 0.412446 Breathing secondhand smoke 0.5983 infant death syndrome 0.453829 smoking 0.508887 National Cancer Institute 0.448359 heart attack‚ 0.429618 kids 0.411336 quiz 0.411311 cigarette 0.405834 coughing‚ extra phlegm‚ 0.454984 bronchitis 0.405901 people 0.432125 home 0.416331 nannies 0.405803 severe attacks 0.428972 best thing 0.428251 shortness 0.406847 ear infections 0.428442 low birth weight 0.454001 family 0.425482	CLICK HERE
16645	National Cancer Institute	Html	en	Understanding “Chemobrain” and Cognitive Impairment after Cancer Treatment	An NCI research update about research to investigate what factors play a role in “chemobrain” or cognitive impairment after cancer treatment.	cognitive problems 0.439925 cognitive behavioral therapy 0.339182 cancer treatment 0.685512 cognitive effects 0.256058 self-reported cognitive functioning 0.391696 lower cognitive performance 0.348528 cognitive decline 0.284161 chemotherapy 0.377855 long-term cognitive changes 0.331518 chemotherapy treatment 0.254041 cognitive challenges 0.286627 cognitive issues 0.282189 Kettering Cancer Center 0.246129 chemotherapy-associated cognitive impairment 0.369163 Wilmot Cancer Institute 0.218061 Dr. Ganz 0.536508 Jonsson Comprehensive Cancer 0.230946	Dr. Ahles 0.527642 cognitive rehabilitation program 0.323502 cognitive changes 0.469428 healthy women 0.234218 breast cancer patients 0.251612 recent research 0.354647 patients 0.34223 Cancer Therapy-Cognitive Function 0.218486 breast cancer survivors 0.783509 cognitive difficulties 0.366868 treatment-related cognitive impairment 0.464189 hormonal therapy 0.233078 self-reported cognitive complaints 0.381226 cognitive symptoms 0.25427 cognitive impairment 0.941275 neuropsychological tests 0.263188	CLICK HERE
17277	National Cancer Institute	Html	null	Cáncer avanzado y quienes cuidan	Si usted cuida a un paciente, puede sentir cansancio y preocupación a medida que se enfrenta al cáncer de su ser querido. Cuidar a alguien con cáncer avanzado trae desafíos y preocupaciones nuevas.			CLICK HERE